| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.35 | 0.04 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.33 | 0.004 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.31 | 0.07 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.31 | 0.04 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.3 | 0.009 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.24 | 0.07 |
| mRNA | BIRB 0796 | FIMM | pan-cancer | AAC | -0.24 | 0.2 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.24 | 0.05 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.23 | 0.1 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.22 | 0.1 |